

CITATION REPORT

List of articles citing

Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study

DOI: 10.1136/bmj.g3596
BMJ, The, 2014, 348, g3596.

Source: <https://exaly.com/paper-pdf/57919028/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
156	Link between FDA antidepressant warnings and increased suicide attempts in young people is questionable. <i>BMJ, The</i> , 2014 , 349, g5614	5.9	2
155	References. 2014 , 175-189		
154	Gefahr durch Infos zu Arzneimittelrisiken?. 2014 , 16, 11-11		
153	Suicidal Behavior After FDA Warnings for Antidepressants. 2014 , 32, 54-54		
152	The FDA warning on antidepressants and suicidality--why the controversy?. 2014 , 371, 1668-71		38
151	Antidepressants' black-box warning--10 years later. 2014 , 371, 1666-8		96
150	Antidepressant use and suicidal behaviour. 2014 , 50, 837-838		
149	Antidepressant use and suicidal behaviour after FDA warnings. 2014 , 1508, 4-4		
148	Excess mortality in bipolar disorders. 2014 , 16, 499		51
147	Antidepressant use and suicidal behaviour after FDA warnings. 2014 , 706, 10-10		
146	[Suicide risk in minors. A new explosive in the antidepressant debate]. 2014 , 156, 28		
145	Acute fluoxetine modulates emotional processing in young adult volunteers. 2015 , 45, 2295-308		16
144	Psychopharmacology: Child and Adolescent. 2015 , 1-14		
143	Depression and violence—what do we really know?. <i>Lancet Psychiatry, the</i> , 2015 , 2, 491-2	23.3	
142	Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1026-35	2.6	7
141	Interventions for self-harm in children and adolescents. <i>The Cochrane Library</i> , 2015 , CD012013	5.2	94
140	Racial/Ethnic differences in health care visits made before suicide attempt across the United States. 2015 , 53, 430-5		67

139	The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression. 2015 , 5, e563		15
138	Depression and violence: a Swedish population study. <i>Lancet Psychiatry</i> , 2015 , 2, 224-32	23.3	115
137	Antidepressant drugs and teenage suicide in Hungary: Time trend and seasonality analysis. 2015 , 19, 221-5		5
136	Effect of Pediatric Behavioral Health Screening and Colocated Services on Ambulatory and Inpatient Utilization. 2015 , 66, 1141-8		17
135	The many different faces of major depression: it is time for personalized medicine. 2015 , 753, 88-104		36
134	Antidepressants and the adolescent brain. 2015 , 29, 545-55		29
133	How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?. 2015 , 37, 1420-1432.e1		7
132	Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. 2015 , 37, 1280-91		9
131	Capsule commentary on Ott et al., do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. 2015 , 30, 347		
130	Incorporating Both Randomized and Observational Data into a Single Analysis. 2015 , 2, 49-72		7
129	Janusian peregrinations and progress. 2015 , 33, 1-2		9
128	Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. 2015 , 8, 15		7
127	Adolescent Depression-Pharmacotherapy or Psychotherapy?. 2016 , 37, 264		4
126	Suicide and Suicide Attempts in Adolescents. 2016 , 138,		200
125	Primary care management of depression in children and adolescents. 2016 , 41, 38-45		4
124	Ketamine and Suicide Risk. 2016 , 43-56		
123	Missing clinical and behavioral health data in a large electronic health record (EHR) system. 2016 , 23, 1143-1149		71
122	The Impact of High-Profile Sexual Abuse Cases in the Media on a Pediatric Emergency Department. 2016 , 25, 627-35		1

121	Antidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?. 2016 , 477-499		
120	Parents' Experiences of Nonsuicidal Self-Injury Among Adolescents and Young Adults. 2016 , 25, 3403-3416		27
119	Recent Advances in Means Safety as a Suicide Prevention Strategy. 2016 , 18, 96		19
118	Major Mood Disorders and Suicidal Behavior. 2016 , 74-92		6
117	Comparing episodes of antidepressants use with intermittent episodes of no use: A higher relative risk of suicide attempts but not of suicide at young age. 2016 , 30, 1000-7		2
116	Predictors of and attitudes toward counseling about SUDEP and other epilepsy risk factors among Austrian, German, and Swiss neurologists and neuropsychiatrists. 2016 , 57, 612-20		40
115	Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. <i>Drug Safety</i> , 2016 , 39, 709-14	5.1	4
114	N-of-1 Policymaking--Tragedy, Trade-offs, and the Demise of Morcellation. 2016 , 374, 986-90		28
113	Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. 2016 , 16, 367-74		22
112	Antidepressants and Suicide Risk: A Challenge. 2016 , 291-302		1
111	Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. 2016 , 87, 329-42		8
110	Suicide and suicidal behaviour. 2016 , 387, 1227-39		819
109	Suicide Behavior Before and After the Start with Antidepressants: A High Persistent Risk in the First Month of Treatment Among the Young. 2015 , 19,		10
108	How do antidepressants influence the BOLD signal in the developing brain?. 2017 , 25, 45-57		6
107	Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment. 2017 , 45, 32-39		11
106	Editorial: Pharmacotherapy and adolescent depression - an important treatment option. 2017 , 22, 59-60		5
105	Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. 2017 , 22, 475-483		4
104	Outpatient antidepressant drug use in children and adolescents in Germany between 2004 and 2011. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 170-179	2.6	19

103	Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice. 2017 , 174, 1203-1213	13
102	A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills. 2017 , 34, 1147-1156	7
101	Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients. 2017 , 73, 1655-1663	2
100	Association Between Contemporary Trends in Inferior Vena Cava Filter Placement and the 2010 US Food and Drug Administration Advisory. 2017 , 177, 1373-1374	28
99	Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder. 2017 , 47, 144-154	41
98	Influences on antidepressant prescribing trends in the UK: 1995-2011. 2017 , 52, 193-200	71
97	Comparative risk of self-harm hospitalization amongst depressive disorder patients using different antidepressants: a population-based cohort study in Taiwan. 2017 , 47, 81-92	6
96	The Impact of the Massachusetts Behavioral Health Child Screening Policy on Service Utilization. 2017 , 68, 25-32	12
95	Antidepressant Use by Youth with Minimal or Mild Depression: Evidence from 3 Health Systems. 2017 , 2, e017	
94	Counter-Point: Early Warning Systems Are Imperfect, but Essential. 2018 , 56, 382-383	4
93	Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. 2018 , 56, 365-372	8
92	Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 413-421	6.5 9
91	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005-2011. 2018 , 55, 907-914	1
90	Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning. 2018 , 69, 389-395	8
89	The Role of HIPAA Omnibus Rules in Reducing the Frequency of Medical Data Breaches: Insights From an Empirical Study. 2018 , 96, 144-166	16
88	Product Recall Decisions in Medical Device Supply Chains: A Big Data Analytic Approach to Evaluating Judgment Bias. 2018 , 27, 1816-1833	21
87	Use of assisted reproductive technologies before and after the Artificial Reproduction Act in Taiwan. <i>PLoS ONE</i> , 2018 , 13, e0206208	3.7 6
86	Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. 2018 , 10, 37-43	9

85	Response to 'Comment on 'Measuring the impact of medicines regulatory interventions - systematic review and methodological considerations' by Goedecke et al.'. 2018 , 84, 2169-2170	2
84	Comment on 'Measuring the impact of medicines regulatory interventions - systematic review and methodological considerations' by Goedecke et al. 2018 , 84, 2167-2168	2
83	Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization. 2018 , 38, 1125-1133	2
82	Counter-Point: Staying Honest When Policy Changes Backfire. 2018 , 56, 384-390	5
81	Hospitalization for Suicide Ideation or Attempt: 2008-2015. 2018 , 141,	181
80	Psychotropic medication in children and adolescents in the United States in the year 2004 vs 2014. 2018 , 26, 5-10	19
79	An Introduction to the Point/Counter-Point/Reply Exchange by Dr Stone and Professor Lu and Colleagues. 2018 , 56, 373-374	1
78	In Search of a Pony: Sources, Methods, Outcomes, and Motivated Reasoning. 2018 , 56, 375-381	3
77	A methodological framework for model selection in interrupted time series studies. 2018 , 103, 82-91	54
76	Measuring the impact of pharmacovigilance activities, challenging but important. 2019 , 85, 2235-2237	8
75	Evaluating and Improving Physician Prescribing. 2019 , 411-436	
74	Sensory Integration and Functional Reaching in Children With Rett Syndrome/Rett-Related Disorders. 2019 , 13, 1179556519871952	1
73	Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden. 2019 , 28, 1137-1145	19
72	Denying renal transplantation to an adolescent medical cannabis user: An ethical case study. 2019 , 23, e13467	7
71	Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature. <i>Drug Safety</i> , 2019 , 42, 1125-1134	5.1 5
70	Association Between Parental Medical Claims for Opioid Prescriptions and Risk of Suicide Attempt by Their Children. 2019 , 76, 941-947	16
69	The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. <i>Frontiers in Psychiatry</i> , 2019 , 10, 294	5 23
68	Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. 2019 , 9, e022293	5

67	Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models. 2019 , 617-638		5
66	Predictors of re-attempt in a cohort of suicide attempters: A survival analysis. 2019 , 247, 20-28		30
65	Identifying Preanalytic and Postanalytic Laboratory Quality Gaps Using a Data Warehouse and Structured Multidisciplinary Process. 2019 , 143, 518-524		3
64	Joven, Extranjera, y Deprimida en América: Ruminations of an Immigrant to Prozac Nation. 2019 , 19, 243-255		
63	Reduction in Upper Limb Joint Surgery Among Rheumatoid Arthritis Patients: An Interrupted Time-Series Analysis Using Danish Health Care Registers. 2020 , 72, 274-282		5
62	Trends in antidepressant use among children and adolescents: a Scandinavian drug utilization study. <i>Acta Psychiatrica Scandinavica</i> , 2020 , 141, 34-42	6.5	6
61	Assessing the Benefits of Integrating Health Information Exchange Services into the Medical Practices Workflow. 2020 , 23, 599		3
60	End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. <i>PLoS ONE</i> , 2020 , 15, e0234541	3.7	2
59	Interventions for self-harm in children and adolescents. <i>The Cochrane Library</i> , 2020 ,	5.2	1
58	FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1022-1029	2.6	2
57	Increases in Suicide Deaths Among Adolescents and Young Adults Following US Food and Drug Administration Antidepressant Boxed Warnings and Declines in Depression Care. <i>Psychiatric Research and Clinical Practice</i> , 2020 , 2, 43-52	2.7	3
56	Commentary: Duty to Warn: Antidepressant Black Box Suicidality Warning is Empirically Justified. <i>Frontiers in Psychiatry</i> , 2020 , 11, 363	5	2
55	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020 , 7, 581-601	23.3	58
54	Multiple sclerosis coverage in the written media of a low prevalence country. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102266	4	1
53	New generation antidepressants for depression in children and adolescents: a network meta-analysis. <i>The Cochrane Library</i> , 2020 ,	5.2	0
52	Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified. <i>Frontiers in Psychiatry</i> , 2020 , 11, 18	5	22
51	Technology-Enabled Outreach to Patients Taking High-Risk Medications Reduces a Quality Gap in Completion of Clinical Laboratory Testing. <i>Population Health Management</i> , 2020 , 23, 3-11	1.8	6
50	Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling. <i>Research Policy</i> , 2021 , 50, 104126	7.5	2

49	Relationship between suicide rate and antidepressant prescription: An ecological study in the People's Republic of China. <i>Human Psychopharmacology</i> , 2021 , 36, 1-9	2.3	0
48	Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. <i>Drug Safety</i> , 2021 , 44, 589-600	5.1	1
47	Black Box Warning Did Not Cause Increased Suicides. <i>Psychiatric Research and Clinical Practice</i> , 2021 , 3, 97-97	2.7	1
46	Prevalence and Childhood Precursors of Opioid Use in the Early Decades of Life. <i>JAMA Pediatrics</i> , 2021 , 175, 276-285	8.3	2
45	Response to Black Box Warning Did Not Cause Increased Suicides. <i>Psychiatric Research and Clinical Practice</i> , 2021 , 3, 98-101	2.7	0
44	Interventions for self-harm in children and adolescents. <i>The Cochrane Library</i> , 2021 , 3, CD013667	5.2	5
43	Enhancing Regulatory Decision Making for Postmarket Drug Safety. <i>Management Science</i> ,	3.9	2
42	New generation antidepressants for depression in children and adolescents: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 5, CD013674	5.2	3
41	Use of Medications in Suicide Prevention. 2021 , 149-170		
40	Youth and Adolescents. 2021 , 216-236		
39	Depression. <i>Annals of Internal Medicine</i> , 2021 , 174, ITC65-ITC80	8	15
38	When Can We Trust Real-World Data To Evaluate New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	5
37	Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use. <i>Addiction Research and Theory</i> , 1-8	2.6	3
36	Utility of item 9 of the patient health questionnaire in the prospective identification of adolescents at risk of suicide attempt. <i>Suicide and Life-Threatening Behavior</i> , 2021 , 51, 854-863	3.9	1
35	Suicidality and self-injury with selective serotonin reuptake inhibitors in youth: Occurrence, predictors and timing. <i>Acta Psychiatrica Scandinavica</i> , 2021 ,	6.5	0
34	The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. <i>Lancet Psychiatry</i> , 2021 , 8, 824-835	23.3	7
33	Introduction: specific disease areas. 2021 , 43-262		
32	Do drug-related safety warnings have the expected impact on drug therapy? A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 229-251	2.6	7

31	Safety and Tolerability of Antidepressants. 2016 , 149-166		1
30	Depressive Störungen. 2017 , 1711-1817		1
29	Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study. <i>PLoS Medicine</i> , 2015 , 12, e1001875	11.6	34
28	Impact of class-level labelling change on prescriptions of antidepressants for adolescents: An interrupted time-series study using a health insurance claims database in Japan, 2005-2013. <i>PLoS ONE</i> , 2020 , 15, e0243424	3.7	2
27	The effect of television and print news stories on the nocebo responding following a generic medication switch. <i>Clinical Psychology in Europe</i> , 2020 , 2,	2.5	2
26	Antidepressants and suicidality: History, the black-box warning, consequences, and current evidence. <i>Mental Health Clinician</i> , 2015 , 5, 202-211	1.6	21
25	Effect of regulatory interventions on agomelatine use in Spain: A multiple intervention time-series analysis in a nationwide electronic healthcare record database. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6	
24	Trends in Ketamine Use, Exposures, and Seizures in the United States up to 2019. <i>American Journal of Public Health</i> , 2021 , 111, 2046-2049	5.1	3
23	Pharmacoepidemiological Approaches in Health Care. 2015 , 197-222		
22	Depressive Störungen. 2016 , 1-107		
21	Black-Box Warning for Antidepressants. <i>MOJ Bioequivalence & Bioavailability</i> , 2016 , 2,		
20	Starting Young: Children Cultured into Becoming Psycho-Pharmaceutical Consumers—the Example of Childhood Depression. 2017 , 51-71		
19	Antidepressants and Suicide Risk: Harmful or Useful?. 2017 , 329-347		1
18	Zentrales Nervensystem. 2018 , 253-445		
17	Cannabis and Neuropsychiatric Effects. 2020 , 65-132		
16	Pharmacoepidemiological Approaches in Health Care. 2020 , 171-202		
15	A Multilayered Research Framework for Humanities and Epidemiology of Medicinal Product Risk Communication. 2020 , 1-84		0
14	Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS). <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 141-63	1	5

13	Status Update on the Sheehan-Suicidality Tracking Scale (S-STs) 2014. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 93-140	1	12
12	Evaluation of psychometric properties of the maastricht upper extremity questionnaire (MUEQ) in iranian computer users. <i>Journal of Education and Health Promotion</i> , 2021 , 10, 245	1.4	
11	Zentrales Nervensystem. 2022 , 301-510		
10	Effect of the FDA Black Box Suicidality Warnings for Antidepressants on Suicide Rates in the USA.. <i>Crisis</i> , 2021 ,	2.8	1
9	Depression and Anxiety Disorders. 305-450		
8	Cancer therapies: Caveats, concerns, and momentum. 2022 , 401-430		
7	Neurobiology of Suicide in Children and Adolescents: Implications for Assessment and Treatment. 2022 , 13-19		0
6	Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making. 2022 ,		0
5	FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder.		0
4	The Mediterranean Diet and the Western Diet in Adolescent Depression-Current Reports. 2022 , 14, 4390		2
3	A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actions.		0
2	US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics. <i>bmjebm-2022-112005</i>		0
1	Pharmacologic Approaches to Suicide Prevention. 2023 , 21, 137-144		0